The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
AndreT., LouvetC., Maindrault-GoebelF.CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-Fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer.1999; 35(9): 1343–1347.
2.
TournigandC., AndreT., AchilleE.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol.2004; 22(2): 229–237.
3.
TeufelA., SteinmannS., SieblerJ.Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer.2004; 4(1): 38.
4.
National Comprehensive Cancer Network.NCCN practice guidelines – colon cancer. Available at http://www.nccn.org/. Accessed on January 14, 2005.
5.
DouillardJ.Y., CunninghamD., RothA.D.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet.2000; 355(9209): 1041–1047.
6.
SouglakosJ., ZirasN., PolyzosA.Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): preliminary results of a multicenter randomized phase III trial [abstract]. J Clin Oncol.2004; 22(14S): 3532.
7.
RougierP., RaoulJ.L., Van LaethemJ.L.Cetuximab +FOLFIRI as first-line treatment for metastatic colorectal CA [abstract]. J Clin Oncol.2004; 22(14S): 3513.
8.
MessersmithW.A., LaheruD.A., SenzerN.N.Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774). Clin Cancer Res.2004; 10(19): 6522–6527.
9.
TrisselL.A.Handbook on Injectable Drugs.12th ed.Bethesda, MD: American Society of Health-System Pharmacists; 2003. 811–812.
10.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
11.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56(8): 729–764.
12.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Available at: www.nccn.org. Accessed on January 14, 2005.
13.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17(9): 2971–2994.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol.2003; 30(suppl 1): 10–17.
18.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18(20): 3558–3585.
19.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
20.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
21.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
22.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
23.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 494–504.
24.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
25.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6(2): 162–176.
26.
RaymondE., BoigeV., SandrineF.Dosage adjustment and pharmacokineticprofile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol.20(21): 4303–4312.
